Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sevencan Beyza, Steenackers Nele, van Laar Amar Daniël Emanuel, Pazmiño Lucio Sofía, Buyse Bertien, Kalkanis Alexandros, Testelmans Dries, Van der Schueren Bart
Аннотация
STUDY OBJECTIVES: To assess the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in the treatment of obstructive sleep apnea.
METHODS: A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.
RESULTS: Emerging evidence indicates that SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. Although these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the apnea-hypopnea index and potential improvements in other sleep-related outcomes.
CONCLUSIONS: There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.
CITATION: Sevencan B, Steenackers N, van Laar ADE, et al. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. J Clin Sleep Med. 2025;21(8):1433-1444.
METHODS: A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.
RESULTS: Emerging evidence indicates that SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. Although these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the apnea-hypopnea index and potential improvements in other sleep-related outcomes.
CONCLUSIONS: There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.
CITATION: Sevencan B, Steenackers N, van Laar ADE, et al. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. J Clin Sleep Med. 2025;21(8):1433-1444.